儿童低级别胶质瘤出血发生率与预测因素
该回顾性队列研究纳入236例儿童低级别胶质瘤患者(2011-2025年),分析肿瘤出血的发生率、时机及独立危险因素。KIAA1549::BRAF融合与出血最强相关(多变量模型中约6倍风险),MAPK抑制剂暴露和脑脊液分流进一步修饰风险。
要点
- 儿童低级别胶质瘤出血罕见但为晚期并发症,中位发生于诊断后6.4年。
- KIAA1549::BRAF融合与出血风险约6倍升高相关,但受事件数少限制。
- MAPK抑制剂暴露和脑脊液分流可能进一步增加特定部位出血风险。
核心结论
- 儿童低级别胶质瘤出血是罕见的晚期并发症,与肿瘤生物学相关,KIAA1549::BRAF融合可能识别高风险亚组。
研究设计与样本
- 单中心回顾性队列研究,纳入236例儿童低级别胶质瘤患者,时间跨度为2011年至2025年。
- 采用Kaplan-Meier法和Cox比例风险模型进行时间-事件分析,并用惩罚回归减轻过拟合。
主要发现
- 出血通常发生于初始肿瘤诊断后数年,中位时间为6.4年。
- KIAA1549::BRAF融合与出血关联最强,多变量模型中约6倍风险增加,但估计受低事件数限制。
- MAPK抑制剂暴露(具体为binimetinib和tovorafenib)在单变量分析中与出血相关,部分被融合状态混杂。
- 脑脊液分流在脑干、视路和下丘脑位置独立增加风险;无遗传综合征患者发生出血。
临床怎么用
- 对携带KIAA1549::BRAF融合的儿童低级别胶质瘤患者,应考虑生物学指导的出血监测策略。
- 接受MAPK抑制剂或脑脊液分流的患者需个体化管理,警惕出血风险。
局限性
- MAPK抑制剂暴露与出血的关联可能受融合状态混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pediatric low-grade gliomas (pLGGs) typically have excellent long-term outcomes; intratumoral hemorrhage is a rare, potentially dangerous complication. Hemorrhage risk in the context of molecular alterations and targeted therapies remains poorly characterized. We analyzed the incidence, timing, and independent risk factors for hemorrhage in a large contemporary pLGG cohort. METHODS: We conducted a retrospective cohort study of 236 children with pLGG treated at a single center (2011-2025). Clinical, radiographic, and molecular variables were abstracted. The primary endpoint was spontaneous tumoral hemorrhage. Time-to-event analyses utilized Kaplan-Meier methods and Cox proportional hazards modeling; penalized regression mitigated overfitting given the event rarity. RESULTS: Twelve patients (5.1%) experienced hemorrhage over 2,234 person-years (incidence: 0.54/100 person-years). Hemorrhage typically occurred years after initial tumor diagnosis (median 6.4 years). The presence of a KIAA1549::BRAF fusion in the tumor had the strongest association with hemorrhage, persisting across multivariable models (approximately sixfold increased risk), although estimates were limited by low event number. MAPK inhibitor exposure (specifically binimetinib and tovorafenib) was associated with hemorrhage in univariate analysis but partially confounded by fusion status. CSF diversion independently increased risk at brainstem, optic pathway, and hypothalamic locations. No hemorrhages occurred among patients with underlying genetic syndromes, including neurofibromatosis type 1 and tuberous sclerosis. CONCLUSION: Hemorrhage in pLGG is an infrequent late complication associated with tumor biology. KIAA1549::BRAF fusion may identify a higher-risk subgroup, with MAPK inhibitor exposure and CSF diversion further modifying risk. These findings support biology-informed surveillance and personalized management strategies for at-risk children.
引用
- Grin EA, Frome S, Turner J, et al. Incidence and predictors of hemorrhage in pediatric low-grade glioma. J Neurooncol. 2026. PMID: 42414678. doi:10.1007/s11060-026-05699-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。